Cargando…
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
BACKGROUND: CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD1...
Autores principales: | Zhou, Xiaohan, Du, Jun, Liu, Chengdong, Zeng, Hanyi, Chen, Yuting, Liu, Li, Wu, Dehua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299557/ https://www.ncbi.nlm.nih.gov/pubmed/34305920 http://dx.doi.org/10.3389/fimmu.2021.688215 |
Ejemplares similares
-
HILPDA Is a Prognostic Biomarker and Correlates With Macrophage Infiltration in Pan-Cancer
por: Liu, Chengdong, et al.
Publicado: (2021) -
CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis
por: Ye, Wenrui, et al.
Publicado: (2021) -
IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
por: Liu, Chengdong, et al.
Publicado: (2022) -
Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma
por: Zhou, Xiaohan, et al.
Publicado: (2021) -
A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
por: Li, He, et al.
Publicado: (2022)